This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Perrigo Company PLC
Drug Names(s): ELND004
Description: ELND004 is a small molecule that can selectively block particular alpha 4 integrin interactions. The drug is designed to be a follow on oral to Tysabri which blocks alpha-4 beta-1 integrin. Alpha 4 integrins are found on most types of white blood cells. The migration of white blood cells into tissue is part of the body's normal response during inflammation. This inflammatory response can be severely damaging or even life threatening when it is directed against the body's own tissue in autoimmune diseases and may cause serious collateral injury in chronic immune inflammatory diseases.
Perrigo and Elan
In December 2013, Perrigo and Elan announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion. In connection with the acquisition, Perrigo and Elan have been combined under a new company incorporated in Ireland and have adopted the global name Perrigo Company plc. Shares of Perrigo will trade on the New York Stock Exchange and the Tel Aviv Stock Exchange under the ticker symbol PRGO. The scheme of arrangement to effect Perrigo's acquisition of Elan has taken effect today, and Elan shareholders will receive the consideration to which they are entitled under the scheme of arrangement within 14 days.
Perrigo and Mylan
In April 2015, Mylan announced that Mylan has made a proposal to acquire Perrigo in a cash-and-stock transaction. Under the terms of the non-binding proposal, which was delivered to Perrigo's Chairman on April 6, 2015,...See full deal structure in Biomedtracker
Additional information available to subscribers only: